Literature DB >> 21757756

Involvement of PRIP, phospholipase C-related, but catalytically inactive protein, in bone formation.

Koshiro Tsutsumi1, Miho Matsuda, Miho Kotani, Akiko Mizokami, Ayako Murakami, Ichiro Takahashi, Yoshihiro Terada, Takashi Kanematsu, Kiyoko Fukami, Tadaomi Takenawa, Eijiro Jimi, Masato Hirata.   

Abstract

PRIP (phospholipase C-related, but catalytically inactive protein) is a novel protein isolated in this laboratory. PRIP-deficient mice showed increased serum gonadotropins, but decreased gonadal steroid hormones. This imbalance was similar to that for the cause of bone disease, such as osteoporosis. In the present study, therefore, we analyzed mutant mice with special reference to the bone property. We first performed three-dimensional analysis of the femur of female mice. The bone mineral density and trabecular bone volume were higher in mutant mice. We further performed histomorphometrical assay of bone formation parameters: bone formation rate, mineral apposition rate, osteoid thickness, and osteoblast number were up-regulated in the mutant, indicating that increased bone mass is caused by the enhancement of bone formation ability. We then cultured primary cells isolated from calvaria prepared from both genotypes. In mutant mice, osteoblast differentiation, as assessed by alkaline phosphatase activity and the expression of osteoblast differentiation marker genes, was enhanced. Moreover, we analyzed the phosphorylation of Smad1/5/8 in response to bone morphogenetic protein, with longer phosphorylation in the mutant. These results indicate that PRIP is implicated in the negative regulation of bone formation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21757756      PMCID: PMC3162462          DOI: 10.1074/jbc.M111.235903

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  47 in total

Review 1.  Regulation of osteoblast formation and function.

Authors:  J E Aubin
Journal:  Rev Endocr Metab Disord       Date:  2001-01       Impact factor: 6.514

Review 2.  Perspective: the ovarian follicle--a perspective in 2001.

Authors:  J S Richards
Journal:  Endocrinology       Date:  2001-06       Impact factor: 4.736

3.  Interaction of p130 with, and consequent inhibition of, the catalytic subunit of protein phosphatase 1alpha.

Authors:  K Yoshimura; H Takeuchi; O Sato; K Hidaka; N Doira; M Terunuma; K Harada; Y Ogawa; Y Ito; T Kanematsu; M Hirata
Journal:  J Biol Chem       Date:  2001-03-02       Impact factor: 5.157

4.  Mineral trioxide aggregate inhibits osteoclastic bone resorption.

Authors:  D Hashiguchi; H Fukushima; H Yasuda; W Masuda; M Tomikawa; K Morikawa; K Maki; E Jimi
Journal:  J Dent Res       Date:  2011-04-29       Impact factor: 6.116

5.  Identification and characterization of a new phospholipase C-like protein, PLC-L(2).

Authors:  M Otsuki; K Fukami; T Kohno; J Yokota; T Takenawa
Journal:  Biochem Biophys Res Commun       Date:  1999-12-09       Impact factor: 3.575

6.  The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation.

Authors:  Kazuhisa Nakashima; Xin Zhou; Gary Kunkel; Zhaoping Zhang; Jian Min Deng; Richard R Behringer; Benoit de Crombrugghe
Journal:  Cell       Date:  2002-01-11       Impact factor: 41.582

7.  Role of the PLC-related, catalytically inactive protein p130 in GABA(A) receptor function.

Authors:  Takashi Kanematsu; Il-Sung Jang; Taku Yamaguchi; Hiroyasu Nagahama; Kenji Yoshimura; Kiyoshi Hidaka; Miho Matsuda; Hiroshi Takeuchi; Yoshio Misumi; Keiko Nakayama; Tsuneyuki Yamamoto; Norio Akaike; Masato Hirata; Kei-Ichi Nakayama
Journal:  EMBO J       Date:  2002-03-01       Impact factor: 11.598

8.  Runx2 is a common target of transforming growth factor beta1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12.

Authors:  K S Lee; H J Kim; Q L Li; X Z Chi; C Ueta; T Komori; J M Wozney; E G Kim; J Y Choi; H M Ryoo; S C Bae
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

9.  Inhibition of Ca(2+) signalling by p130, a phospholipase-C-related catalytically inactive protein: critical role of the p130 pleckstrin homology domain.

Authors:  H Takeuchi; M Oike; H F Paterson; V Allen; T Kanematsu; Y Ito; C Erneux; M Katan; M Hirata
Journal:  Biochem J       Date:  2000-07-01       Impact factor: 3.857

10.  Cbl associates with Pyk2 and Src to regulate Src kinase activity, alpha(v)beta(3) integrin-mediated signaling, cell adhesion, and osteoclast motility.

Authors:  A Sanjay; A Houghton; L Neff; E DiDomenico; C Bardelay; E Antoine; J Levy; J Gailit; D Bowtell; W C Horne; R Baron
Journal:  J Cell Biol       Date:  2001-01-08       Impact factor: 10.539

View more
  4 in total

1.  Phospholipase C-related, but catalytically inactive protein (PRIP) up-regulates osteoclast differentiation via calcium-calcineurin-NFATc1 signaling.

Authors:  Ayako Murakami; Miho Matsuda; Yui Harada; Masato Hirata
Journal:  J Biol Chem       Date:  2017-03-24       Impact factor: 5.157

2.  Phospholipase C-related but catalytically inactive proteins regulate ovarian follicle development.

Authors:  Miho Matsuda; Masato Hirata
Journal:  J Biol Chem       Date:  2017-03-30       Impact factor: 5.157

3.  Phospholipases of mineralization competent cells and matrix vesicles: roles in physiological and pathological mineralizations.

Authors:  Saida Mebarek; Abdelkarim Abousalham; David Magne; Le Duy Do; Joanna Bandorowicz-Pikula; Slawomir Pikula; René Buchet
Journal:  Int J Mol Sci       Date:  2013-03-01       Impact factor: 5.923

4.  Life-Course Genome-wide Association Study Meta-analysis of Total Body BMD and Assessment of Age-Specific Effects.

Authors:  Carolina Medina-Gomez; John P Kemp; Katerina Trajanoska; Jian'an Luan; Alessandra Chesi; Tarunveer S Ahluwalia; Dennis O Mook-Kanamori; Annelies Ham; Fernando P Hartwig; Daniel S Evans; Raimo Joro; Ivana Nedeljkovic; Hou-Feng Zheng; Kun Zhu; Mustafa Atalay; Ching-Ti Liu; Maria Nethander; Linda Broer; Gudmar Porleifsson; Benjamin H Mullin; Samuel K Handelman; Mike A Nalls; Leon E Jessen; Denise H M Heppe; J Brent Richards; Carol Wang; Bo Chawes; Katharina E Schraut; Najaf Amin; Nick Wareham; David Karasik; Nathalie Van der Velde; M Arfan Ikram; Babette S Zemel; Yanhua Zhou; Christian J Carlsson; Yongmei Liu; Fiona E McGuigan; Cindy G Boer; Klaus Bønnelykke; Stuart H Ralston; John A Robbins; John P Walsh; M Carola Zillikens; Claudia Langenberg; Ruifang Li-Gao; Frances M K Williams; Tamara B Harris; Kristina Akesson; Rebecca D Jackson; Gunnar Sigurdsson; Martin den Heijer; Bram C J van der Eerden; Jeroen van de Peppel; Timothy D Spector; Craig Pennell; Bernardo L Horta; Janine F Felix; Jing Hua Zhao; Scott G Wilson; Renée de Mutsert; Hans Bisgaard; Unnur Styrkársdóttir; Vincent W Jaddoe; Eric Orwoll; Timo A Lakka; Robert Scott; Struan F A Grant; Mattias Lorentzon; Cornelia M van Duijn; James F Wilson; Kari Stefansson; Bruce M Psaty; Douglas P Kiel; Claes Ohlsson; Evangelia Ntzani; Andre J van Wijnen; Vincenzo Forgetta; Mohsen Ghanbari; John G Logan; Graham R Williams; J H Duncan Bassett; Peter I Croucher; Evangelos Evangelou; Andre G Uitterlinden; Cheryl L Ackert-Bicknell; Jonathan H Tobias; David M Evans; Fernando Rivadeneira
Journal:  Am J Hum Genet       Date:  2018-01-04       Impact factor: 11.025

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.